Mojdeh Akbari1, Atieh Abedin Do1, Fakhrolmolouk Yassaee2, Reza Mirfakhraie1,3. 1. Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2. Department of Obstetrics and Gynecology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. Genomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract
BACKGROUND: Uterine leiomyoma, also called fibroid, is a benign tumor that arises due to monoclonal transformation of myometrium, the smooth muscle cell layer of the uterus. Fibroids cause several complications including infertility, miscarriage, bleeding, pain, and dysmenorrhea. Recent studies have revealed the role of mutations in MED12 gene exon 2 in various populations; however, the reported frequency of these mutations differs between reports. In addition, it is suggested that mutations in exon 1 may also play a role in leiomyoma. The aim of the present study was to screen for MED12 exon 1 mutations in leiomyoma tissue samples of Iranian patients. METHODS: We performed mutational analysis of exon 1 and the flanking intronic regions using multi-temperature single-strand conformational polymorphism (MSSCP) and sequencing analyses in 120 uterine leiomyoma samples. RESULTS: No mutations were detected in exon 1 of MED12 in our samples. CONCLUSION: According to the literature and the present results, mutations in the MED12 exon 1 are rare. However, we could not ignore the role of these mutations in developing leiomyoma.
BACKGROUND: Uterine leiomyoma, also called fibroid, is a benign tumor that arises due to monoclonal transformation of myometrium, the smooth muscle cell layer of the uterus. Fibroids cause several complications including infertility, miscarriage, bleeding, pain, and dysmenorrhea. Recent studies have revealed the role of mutations in MED12 gene exon 2 in various populations; however, the reported frequency of these mutations differs between reports. In addition, it is suggested that mutations in exon 1 may also play a role in leiomyoma. The aim of the present study was to screen for MED12 exon 1 mutations in leiomyoma tissue samples of Iranian patients. METHODS: We performed mutational analysis of exon 1 and the flanking intronic regions using multi-temperature single-strand conformational polymorphism (MSSCP) and sequencing analyses in 120 uterine leiomyoma samples. RESULTS: No mutations were detected in exon 1 of MED12 in our samples. CONCLUSION: According to the literature and the present results, mutations in the MED12 exon 1 are rare. However, we could not ignore the role of these mutations in developing leiomyoma.
Authors: Kati Kämpjärvi; Min Ju Park; Miika Mehine; Nam Hee Kim; Alison D Clark; Ralf Bützow; Tom Böhling; Jan Böhm; Jukka-Pekka Mecklin; Heikki Järvinen; Ian P M Tomlinson; Zephne M van der Spuy; Jari Sjöberg; Thomas G Boyer; Pia Vahteristo Journal: Hum Mutat Date: 2014-07-21 Impact factor: 4.878
Authors: Netta Mäkinen; Miika Mehine; Jaana Tolvanen; Eevi Kaasinen; Yilong Li; Heli J Lehtonen; Massimiliano Gentile; Jian Yan; Martin Enge; Minna Taipale; Mervi Aavikko; Riku Katainen; Elina Virolainen; Tom Böhling; Taru A Koski; Virpi Launonen; Jari Sjöberg; Jussi Taipale; Pia Vahteristo; Lauri A Aaltonen Journal: Science Date: 2011-08-25 Impact factor: 47.728
Authors: Megan M McGuire; Alexander Yatsenko; Lori Hoffner; Mirka Jones; Urvashi Surti; Aleksandar Rajkovic Journal: PLoS One Date: 2012-03-12 Impact factor: 3.240